Moderna Raises 2025 Revenue Forecast to $1.9 B, Lifts Expense Outlook
Moderna projects 2025 revenue of about $1.9 billion, exceeding the midpoint of its prior $1.6–$2 billion guidance by ~$100 million. The company raised 2025 GAAP operating expense outlook by $200 million to $5–5.2 billion and forecasts a year-end cash balance near $8.1 billion, factoring in a $0.6 billion term-loan drawdown.
1. Strategic Shift and Break-Even Objective
Moderna has realigned its portfolio to prioritize infectious diseases, oncology and rare diseases as it targets cash break-even by 2028. Following a revenue decline from 2023 into early 2024—driven primarily by lower COVID vaccine demand—the company is focusing R&D resources on its respiratory franchise and high-potential oncology assets. CEO Stéphane Bancel highlighted three FDA-approved respiratory vaccines, two pending flu and flu-plus-COVID submissions, and a norovirus candidate in Phase III, all intended to generate steady cash flow and fund the oncology pipeline without dilutive financing.
2. Revised 2025 Financial Outlook
Moderna now projects full-year 2025 revenue of approximately $1.9 billion, surpassing the midpoint of prior guidance by roughly $100 million. The company has increased its GAAP operating expense forecast by $200 million to a range of $5.0–5.2 billion, reflecting stepped-up investments in mid- and late-stage oncology programs. Year-end cash and marketable securities are expected to total about $8.1 billion, accounting for a planned $600 million drawdown on a newly arranged $1.5 billion term loan facility.
3. 2026 Oncology Catalysts
The upcoming year is pivotal for Moderna’s oncology franchise, with multiple Phase II and III readouts poised to drive valuation inflection points. The Intismeran/Keytruda combination is set for Phase II interim data in mid-2026 and full Phase III results by late 2026, targeting solid tumors with high unmet need. Additional mRNA oncology candidates against neoantigens and shared tumor antigens are advancing into first-in-human studies, potentially expanding the company’s addressable market and underpinning long-term growth beyond respiratory vaccines.
4. Cost Discipline and Pipeline Maturation
Since 2023, Moderna has implemented targeted cost reductions—reducing headcount by 15% in non-core functions and renegotiating manufacturing contracts—to improve operating leverage. R&D spend remains concentrated on 12 mid- and late-stage programs, reflecting a shift from broad platform investments to clinical de-risking. As the pipeline matures, management expects fixed costs to stabilize, enabling higher R&D productivity and freeing cash for select business development opportunities in 2027 and beyond.